Codexis Raises 2021 Revenue Outlook After New Order For Its Enzyme Product

  • Codexis Inc CDXS raised its guidance for 2021 following the receipt of a binding purchase order for up to $13.9 million of a proprietary high-performance enzyme product from an undisclosed pharmaceutical company.
  • Now, the Company expects 2021 total revenues in the range of $89 million to $93 million, up from previous guidance of $82 million to $85 million, higher than the $83.7 million consensus.
  • It expects product revenue in the band of $45 million to $48 million, compared to the earlier outlook of $36 million to $39 million.
  • In addition, the Company also raised 2021 guidance for product gross margin to 60-64%, up from 54-58% guided earlier.
  • HC Wainwright analyst Swayampakula Ramakanth maintained Codexis with a Buy and raised the price target from $26 to $27 (almost 40% upside).
  • Price Action: CDXS shares closed at $19.64 on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CarePrice TargetSmall CapAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!